Overview

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
TG Therapeutics, Inc.
Treatments:
Antibodies, Monoclonal
Bendamustine Hydrochloride